Drugs Made In America Acquisition Corp. — fact timeline

Drugs Made In America Acquisition Corp. amended Amendment No. 2 to the Merger Agreement with Power Analytics Global Corp valued at completed notice address provisions including street addresses and email addresses (effective 2026-04-30).

“Also on April 30, 2026, DMAA and PAGC entered into Amendment No. 2 to the Merger Agreement (“Amendment No. 2,” and together with Amendment No. 1, the “Amendments”) for the purpose of completing the notice address provisions set forth in Section 11.1, including the parties’ respective street addresses and email addresses.”

Drugs Made In America Acquisition Corp. amended Amendment No. 1 to the Merger Agreement with Power Analytics Global Corp valued at revised governing law and jurisdiction provisions, clarified termination provisions, revised notice (effective 2026-04-30).

“On April 30, 2026, DMAA and PAGC entered into Amendment No. 1 to the Merger Agreement (“Amendment No. 1”) for the purpose of correcting certain inconsistencies and incomplete items in the Merger Agreement prior to public disclosure.”

Drugs Made In America Acquisition Corp. entered into Definitive Merger Agreement with Power Analytics Global Corp valued at target enterprise valuation of $1.0 billion, Floor Valuation of $300 million, post-closing ownership (effective 2026-04-29).

“On April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Merger Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”).”

Drugs Made In America Acquisition Corp. shareholders approved Extension Proposal.

“The Extension Proposal was approved by special resolution of the Company’s shareholders, and received the following votes: FOR AGAINST ABSTAIN 18,906,281 4,892,646 0”

Drugs Made In America Acquisition Corp.: Amended charter to extend business combination deadline from April 29, 2026 to April 29, 2027, with up to twelve monthly extensions subject to sponsor deposit (effective 2026-04-27).

“to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month”

Drugs Made In America Acquisition Corp. incurred convertible notes of $100,000 with BV Advisory Partners, LLC at does not bear interest maturing six months from the date of issuance.

“On March 23, 2026, Drugs Made In America Acquisition Corp. (the " Company ") issued an interim convertible note (the " Interim Note ") to BV Advisory Partners, LLC (the " Investor ") in the principal amount of $100,000 (the " Interim Loan ").”

Drugs Made In America Acquisition Corp. entered into Interim Note with BV Advisory Partners, LLC valued at $100,000 (effective 2026-03-23).

“issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000”

Drugs Made In America Acquisition Corp. entered into Investment Agreement with BV Advisory Partners, LLC valued at $500,000 (effective 2026-03-23).

“On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)”

Drugs Made In America Acquisition Corp.: Adopted Second Amended and Restated Memorandum and Articles of Association in connection with the IPO (effective 2025-01-07).

“On January 7, 2025, and in connection with the IPO, the Company adopted its Second Amended and Restated Memorandum and Articles of Association.”